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ABSTRACT PAGE
The treatm ent of schizophrenia is heavily reliant on financial, health, and social care. 
Despite the low occurrence of schizophrenia in the population, the total health care  costs of 
schizophrenia are similar to m ore prevalent mental disorders. Therefore, resources need to 
be directed at finding and implementing the most effective and least costly treatm ent 
regimes. The current study examined differences in weight, lipid and glucose levels, and 
metabolic irregularities between schizophrenic patients receiving first and second 
generation antipsychotics. Results indicated that there w as a  higher prevalence of 
metabolic disorder among patients treated with second generation antipsychotics (SGAs) 
than those treated with first generation antipsychotics (FGAs). Patients receiving SGAs 
also displayed greater increases in weight and systolic blood pressure from first to last 
a sse ssm en t than those being treated with FGAs. Second generation antipsychotics were 
not superior on m easures of clinical efficacy than first generation antipsychotics. In 
combination, these  findings suggest that the benefits of SGAs may not outweigh the side 
effects and financial cost of this c lass of antipsychotics.
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Patterns and Prevalence 1
Patterns and Prevalence of Metabolic Syndrome Among Persons Receiving Treatment
with Antipsychotic Medications 
Schizophrenia is a chronic, deteriorating brain disorder that involves many brain 
and neurochemical abnormalities (Andreasen, 1997; Cahn et al., 2002). Patients with 
schizophrenia evidence psychological, social, cognitive, and occupational deficits 
(Burton, 2006). Compared to the general population, attention/vigilance, working 
memory, verbal and visual learning and memory, reasoning and problem solving, 
processing speed, and social cognition are disturbed in schizophrenics (Ikebuchi, 
Nakagome, & Takahashi, 1999).
Negative symptoms of schizophrenia are often characterized as “deficient 
symptoms” because they reflect deficiencies in normal behavior (Shean, 2004). Negative 
symptoms include: disorganized speech, grossly disorganized or catatonic behavior, 
affective blunting, poverty of speech (alogia), decreased level of activity (avolition), 
decreased pleasure (anhedonia), and poor executive functioning and self care skills 
(American Psychiatric Association [APA], 2000; Worrel, Marken, Beckman, & Ruehter,
2000). Positive symptoms represent an excess in normal behaviors (Toomey, Seidman, 
Lyons, Faraone, & Tsuang, 1999). These symptoms include disorganized thinking, 
hallucinations, and delusions.
Costs o f Schizophrenia
Approximately 1 % of the population is afflicted with schizophrenia (National 
Institute of Mental Health [NIMH], 2005). Despite schizophrenia’s low prevalence, its 
costs are similar to more widespread mental illnesses such anxiety disorders (Rice, 1999). 
In 2002, the economic burden of schizophrenia was approximately $62.7 billion (Wu et
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al., 2005). Included in the overall health care costs of schizophrenia are direct costs (e.g., 
drug and hospitalization costs) and indirect costs (e.g., loss of productivity: 
unemployment, loss of income, and premature death from suicide).
The estimated relapse rate of schizophrenia is as high as 3.5% per month 
(Csemansky & Schuchart, 2002). A minority of schizophrenic patients, approximately 
25% (Bleuer, 1978), fully recover. The remaining percentage of schizophrenics either 
remain in a state of severe psychosis (10%) or experience acute relapses (65%).
Cognitive deficits affecting memory, social skills, and attention can impede a 
schizophrenic's ability to live independently (Velligan et al., 1997) and fulfill social roles 
(Gerlach, 2002). These deficits combined with a high incidence of relapse lead to long 
and/or frequent and expensive hospital stays. The estimated annual cost of 
hospitalizations to relapse among individuals with schizophrenia is $2 billion.
Schizophrenic patients occupy 8.8% of all hospital beds, 11.4% of all nursing 
home beds, and 40.3% of all mental health facility beds (Worrel et al., 2000). Individuals 
who are discharged may still require ongoing and costly outpatient care. Therefore, the 
high economic costs of relapses and re-hospitalizations associated with schizophrenia 
contribute to the high overall health care costs of this disorder.
Comorbidity and Cost
Individuals with schizophrenia often suffer from chronic physical illness (Marder 
et al., 2004). Many medical problems arise due to poor nutrition and hygiene, tobacco 
usage, inadequate treatment, and serious problems associated with side effects of 
antipsychotic medications (Goldman, 1999; Marder et al., 2004; NIMH, 2005; Shean, 
2004). Carney, Jones, and Woolson (2006) found that schizophrenic patients have more
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comorbid medical conditions than those without the disorder. Furthermore, over 33% of 
persons with schizophrenia had three or more comorbid disorders (Carney et al., 2006). 
Carney et al. (2006) found that individuals with schizophrenia have more months of 
follow up and more non-mental health care visits than those without schizophrenia. 
Compared with the general population, individuals with schizophrenia are more likely to 
have respiratory illness even after controlling for the effects of smoking (Sokal et al., 
2004). Current medical problems may exacerbate the psychosis and depression associated 
with schizophrenia (Dixon, Postrado, Delahanty, Fischer, & Lehman, 1999), thus making 
patients more difficult and expensive to treat. The high prevalence of chronic medical 
conditions among individuals with schizophrenia also contributes to increased mortality 
(Brown, 1997).
Results from the Epidemiologic Catchment Area (ECA) Study indicate that 
approximately 47% of individuals with a lifetime diagnosis of schizophrenia or 
schizophreniform disorder also meet the diagnostic criteria for substance abuse. 
Individuals with schizophrenia are 4.6 times more likely of having a substance abuse 
disorder than those without the disorder (Regier et al., 1990). The high prevalence of 
substance abuse and medical problems among schizophrenic patients indicates that the 
cost of care for schizophrenia may be much higher than initial estimates may suggest. 
These indirect costs of schizophrenia may contribute to the large proportion of national 
health care expenditure on schizophrenia worldwide (Beard, Maciver, Clouth, & Riither, 
2006).
Patterns and Prevalence 4
Psychopharmacology o f Schizophrenia
Neurodevelopmental deficits contribute to some of the cognitive and attentional 
impairments evident in schizophrenics even before the onset of overt psychoses. 
Consequently, these impairments may contribute to a schizophrenic's capacity to be 
rehabilitated (Kotrla & Weinberger, 1995; Smith, Hull, Romanelli, Fertuck, & Weiss, 
1999). Although the course of schizophrenia varies, patient outcomes are largely 
determined by medication (Shean, 2004). The American Psychological Association 
(1997) has determined that antipsychotics can lead to a reduction in the relapse rate for 
individuals with schizophrenia. Therefore, long-term psychopharmacological treatment 
may be necessary for improved disease outcomes.
Studies have identified several anatomical abnormalities in the brains of 
schizophrenic patients. However, researchers believe that the symptoms of schizophrenia 
result from circulatory dysfunction rather than localized brain areas (Wiser et al., 1998). 
Some of the biochemical systems that have been implicated in schizophrenia include the 
dopaminergic, glutamate, and the GABA systems (Javitt & Laruelle, 2006).
Dopamine Hypothesis
The dopamine hypothesis is one of the longest lasting and most influential 
explanatory models of schizophrenia (Kapur & Mamo, 2003). According to this 
hypothesis, schizophrenia arises as a result of an excess of the neurotransmitter dopamine 
(DA) in the brain, which is responsible for the positive symptoms characteristic of 
schizophrenia. After the introduction of chlorpromazine in 1952 and other first generation 
antipsychotics (FGAs) shortly after, researchers discovered that the biological mechanism 
underlying schizophrenia involves D2 receptors, one of the two main families of DA
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receptors. This finding was supported by the correlation between the clinical efficacy of 
FGAs and D2 receptor affinity (Horacek et al., 2006; Peroutka & Snyder, 1980). 
Therefore, researchers have historically believed that D2 receptors are the major site of 
action in schizophrenia. According to the dopamine hypothesis, a hyperfunction of DA 
transmission in the striatum accounts for the positive symptoms of schizophrenia. 
Antipsychotics work by antagonizing the D2 receptors, which reduces DA levels in the 
mesolimbic pathway.
First Generation Antipsychotics
Antipsychotics play a central role in the treatment of schizophrenia and other 
psychotic disorders. First generation antipsychotics were formulated to antagonize the D2 
receptor. Research has shown that FGAs effectively reduced positive psychotic 
symptoms. However, FGAs may worsen the negative symptoms of schizophrenia by 
antagonizing DA in the mesocortical pathway where DA is underactive (Shean, 2004).
First generation antipsychotics range in their clinical potency from low to high. 
Low potency drugs include Thorazine (chlorpromazine), Mellaril (thioridazine), and 
Serentil (mesoridazine). Medium potency drugs include Loxatane (loxapine), Moban 
(molindone), and Trilafon (perphenazine). High potency drugs include Haldol 
(haloperidol), Prolixin (fluphenazine), Navane (thioxanthene), and Stelazine 
(trifluoperazine) (Worrel et al., 2000).
Extra-pyramidal side effects. First generation antipsychotics often produce 
extrapyramidal symptoms (EPS). Caesy (1998) estimated that up to 90% of patients on 
FGAs experience EPS. The nigrostriatal pathway is involved in the presence of EPS such 
as dystonia, akathisia, and concomitant movement disorders. Dopamine antagonism at
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receptor sites in these pathways produces motor dysfunction and other symptoms bearing 
resemblance to Parkinson’s disease (Weiden, 2007). According to the DSM-IV-TR, 
neuroleptic induced parkinsonism is “Parkinsonian tremor, muscular rigidity, or akinesia 
developing within a few weeks of starting or raising the dose of a neuroleptic medication 
(or after reducing a medication used to treat extrapyramidal symptoms)” (APA, 2000, p. 
735). In order for EPS that affects motor functionality to arise, there needs to be an 80% 
loss of DA content in the striatal area of the basal ganglia (Weiden, 2007). According to a 
PET study, patients consistently report EPS when they are receiving neuroleptic drugs at 
doses that involve an occupancy rate of over 80% at the D2 receptor (Farde, Mack, 
Nyberg, & Halldin, 1997).
Due to the physical discomfort and social stigma associated with EPS, FGAs 
producing these side effects often lead to a lower quality of life (Strejilevich et al., 2005), 
poor treatment compliance (Buchanan, 1992), and increased mortality rates (Ballesteros, 
Gonzalez-Pinto, & Bulbena, 2000). Patients with severe EPS also demonstrate impaired 
perception and cognitive functioning (Krausz, Moritz, Naber, Lambert, & Andresen, 
1999). Because treatments for EPS often demonstrate minimal effectiveness (Soares & 
McGrath, 1999), EPS are often unavoidable and severe limitations of FGAs.
Other FGA side effects. Hyperprolactinemia is a common side effect of FGAs. By 
occupying D2 receptors, FGAs cause a disinhibition of plasma prolactin levels by 
blocking DA release (Ben-Jonathan & Hnasko, 2001). This inhibition of DA results in 
elevated prolactin levels. Hyperprolactinemia can cause sexual side effects such as 
irregular menstruation, lactation in women and men, and sexual dysfunction in men.
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Most FGAs, chlorpromazine and thioridazine in particular, have anticholinergic 
actions (Crook, Tomaskovic-Crook, Coplov, & Dean, 2001). Administration of these 
neuroleptic drugs increases the activity of presynaptic receptors in the central and 
peripheral nervous symptoms that inhibit the release of acetylcholine (ACh), thus 
depleting Ach levels (Lacroix, Hows, Shah, Hagan, & Heidbreder, 2003; Snyder, 
Greenburg, & Yamamura, 1974). Depleted ACh levels lead to memory and learning 
impairments (Kasper & Resinger, 2003). Other anticholinergic effects include dry mouth, 
constipation, retention of urine, and blurred vision. The elderly are especially sensitive to 
the anticholinergic effects of FGAs. High-potency FGAs are less anticholinergic and less 
sedating than lower potency FGAs (Zhang & Bymaster, 1999). However, these high- 
potency agents are more likely to cause parkinsonism, akathesia, and dystonia 
(Mukherjee, 1982; Snyder et al., 1974; Tarsy & Baldessarini, 2006). Because many 
FGAs block DA transmission and have anticholinergic effects at muscarinic receptors 
(Crook et al., 2001), these neuroleptics are more likely to produce tardive dyskinesia than 
other neuroleptic drugs (Sayers, Burki, Ruch, & Asper, 1976).
Second Generation Antipsychotics
Second generation antipsychotics (SGAs) were introduced in the United States in 
late 1980s. In 1989, clozapine (Clozaril) was the first SGAs antipsychotic to be approved 
by the Food and Drug Administration (FDA). Other SGAs include: Risperdal 
(risperidone) Zyprexa (olanzapine), Seroquel (quetiapine), Geodon (ziprasidone), and 
Ability (aripiprazole). Second generation antipsychotics are characterized by a higher 5- 
HT2/DA2 occupancy ratio than FGAs (Mamo et al., 2004). Studies have shown that 
SGAs effectively reduce positive (Bouchard et al., 2000) and negative symptoms
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(Martyns-Yellowe, 1994), and the risk of relapse for schizophrenic patients without the 
traditional side effects associated with FGAs (Haro & Salvador-Carulla, 2006). Because 
SGAs demonstrate fewer and less severe EPS across all age groups (Correll, Leucht, & 
Kane., 2004; Weiden, 2007), SGAs may contribute to a higher quality of life and greater 
treatment compliance among schizophrenic patients than FGAs (Gerlach, 1999). Thus, 
some have argued that SGAs have the capacity to diminish the incidence of acute 
psychotic episodes that are responsible for frequent and long-lasting hospital stays. As a 
result, SGAs have become the preferred pharmacotherapy for schizophrenia (Correll et 
al., 2004).
Side effects o f SGAs. In addition to the potential benefits of SGAs, this class of 
antipsychotics also has its own financial costs and medical risks. EPS is still a distressful 
and problematic side effect of many SGAs, especially in elderly populations. Research 
suggests that taking a high dose of some SGAs increases the risk of EPS (Correll et al., 
2004; Kane, 2001). Therefore, EPS is still common among schizophrenic patients taking 
higher than recommended doses of SGAs such as clozapine, risperidone and olanzapine 
(Correll et al., 2004; Weiden, 2007).
One of the major limitations of SGAs is weight gain (Weiden, 2007). Weight gain 
associated with SGAs increases the risk of developing metabolic syndrome (MS). 
Research suggests that individuals whose weight increases by 5% are 200 times more 
likely to develop MS (Everson et al., 1998). Therefore, patients taking SGAs are more 
vulnerable to developing MS than individuals on FGAs.
The metabolic abnormalities associated with SGAs also increase the risk of 
developing MS. Diagnosis for MS is established when there is a co-occurrence of at least
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three of the following conditions: elevated triglycerides, HDL cholesterol, blood 
pressure, fasting glucose levels, and abdominal obesity (Expert Panel on Detection,
2001). Metabolic syndrome elevates the risk for cardiovascular disease, which is one of 
the leading causes of morbidity and mortality among schizophrenic patients (Meyer, 
2003). The insulin sensitivity and other metabolic abnormalities associated with MS often 
predict diabetic complications. Metabolic syndrome can exacerbate pre-existing diabetes 
mellitus or can significantly increase the risk of developing this condition (Newcomer et 
al., 2002). Compared to the general population, individuals with schizophrenia are twice 
as likely to be diagnosed with type 2 diabetes mellitus (Dixon et al., 2000).
The increased morbidity and mortality rates for many of the conditions associated 
with MS (e.g., obesity, diabetes mellitus, and cardiovascular disease) emphasize the 
public health implications of SGAs (Jin, Meyer, & Jeste, 2004). Weight gain associated 
with medication use often leads to treatment noncompliance (Baptista, 1999). 
Schizophrenics with poor treatment compliance relapse more frequently than those who 
comply with treatment. Therefore, weight gain associated with the use of SGAs may lead 
to poor treatment prognosis. Not all SGAs have the same side effect profiles. However, 
the potentially harmful side effects of SGAs and high medical costs associated with 
assessment and treatment of abnormalities in glucose and lipid metabolism (Nichols & 
Brown, 2005) may counter-balance the potential benefits associated with these drugs. 
Current Study
The treatment of schizophrenia is heavily reliant on financial, health, and social 
care. Therefore, resources need to be directed at finding and implementing the most 
effective and least costly treatment regimes. Many patients and clinicians discontinue
Patterns and Prevalence 10
antipsychotic treatments due to adverse side effects. Therefore, the goal of 
pharmacological treatments for schizophrenia is to maximize treatment effectiveness 
while limiting the number of side effects that lessen patients’ quality of life. Because 
SGAs are associated with a reduced risk of EPS, researchers believed that the potential 
clinical benefits of SGAs outweighed the costs associated with these drugs. However, 
recent research has suggested that SGAs may not be superior to FGAs in terms of clinical 
efficacy (Geddes, Freemantle, Harrison, & Bebbington, 2000). Furthermore, the potential 
side effects (e.g., weight gain, metabolic abnormalities) associated with SGAs may 
suggest that the medial risks and financial costs of these drugs counterbalance the 
benefits of SGAs. Therefore, the aim of this study is to compare differences in weight, 
lipid and glucose levels, and metabolic irregularities between individuals on first and 
second generation antipsychotics while controlling for length of hospital stay and 
psychosis. It is hypothesized that patients treated with SGAs will display more weight 
gain and a higher prevalence of MS than individuals on FGAs. First generation 
antipsychotics such as perphenazine and haloperidol appear to be just as effective in 
treating schizophrenia as the following SGAs: quetiapine, risperidone, and ziprasidone 
(Lieberman et al., 2005; Rosenheck et al., 2006). Therefore, it is hypothesized that FGAs 
and SGAs will demonstrate similar clinical efficacy when collapsing across drug type.
Method
Research Design
Study participants were patients at Eastern State Hospital in Williamsburg, 
Virginia. A research proposal was submitted and approved by the hospital's Institutional 
Review Board (IRB). The research design was a retrospective, archival study of the
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medical files of patients. A list of patients admitted to Eastern State Hospital between 
1990 and 1999 and being treated with an FGA was randomly generated from admission 
records. An additional list of patients admitted to Eastern State Hospital between 2000 
and 2006 and receiving treatment with an SGA was also created. From these lists, only 
current or past patients receiving treatment with an FGA or SGA for at least a six-month 
period were chosen for inclusion in the study. Individuals concurrently taking SGAs and 
FGAs were excluded from participation in the study. Demographic, clinical, and medical 
data were collected from patient files. Clinical and medical data were collected at two 
points in time in order to evaluate change in disease course across time. A pre-treatment 
assessment of the clinical variables was taken during the first month of admission into the 
hospital. The most current or discharge assessment of clinical and medical variables was 
recorded during December 2006. A standard de-identification process was used to protect 
patient confidentiality and anonymity. Participants’ names, hospital record numbers, and 
a unique ID number were maintained on a Master Subjects Form.
Table 1 lists gender, ethnicity, and education history. Ages at last assessment 
ranged from 19 to 74 years (M  = 44.20; Mdn = 44.00; SD = 12.09). Number of 
admissions to a state psychiatric facility (including current admission) ranged from 1 to 
24 (M = 6.62; Mdn = 5.00; SD = 5.59). Participants length of stay in the hospital ranged 
from 0.21 to 13.99 years (M = 1.94; Mdn = 1.04; SD = 2.14). Table 2 lists Axis I and II 
psychiatric diagnoses, and Axis IV psychosocial/environmental problems. Number of 
Axis III medical conditions ranged from 0 to 8 (.M  = 2.29; Mdn = 2.00; SD = 2.03).
Table 3 lists antipsychotic doses. Tables 4 and 5 list the prevalence of MS among patients 
receiving FGAs and SGAs.
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Variables
A data collection form was developed to review each patient file. Demographic 
variables collected included: age, gender, ethnicity, education history of the patient, 
length of stay at hospital (LOS). Clinical variables were Axis I, II, III, IV, V (Global 
Assessment of Functioning) diagnoses from the DSM-IV-TR (American Psychological 
Association, 2000), Brief Psychiatric Rating Scale (BPRS) scores, and Mini Mental State 
Exam (MMSE) scores. The BPRS (Overall & Gorham, 1962) is a scale designed to 
measure the severity of psychiatric symptoms. The MMSE is used to assess cognitive 
status in areas of orientation, memory, and attention (Folstein, Folstein, & McHugh, 
1975). Medical variables included the following: medications and their administered 
dosages, weight (lbs), BMI, blood pressure, and glucose and lipid levels.
Results
Statistical Measures
Frequency distributions were run on demographic variables (gender, age, 
ethnicity, education, and diagnoses), clinical treatment efficacy variables (Global 
Assessment of Functioning [GAF], BPRS total score, five BPRS scale scores, MMSE) at 
each time interval, and physiological variables (diagnosis of MS, BMI (body mass 
index), blood pressure, HDL, Triglycerides, and fasting glucose) at each time period. 
Measures of central tendency, dispersion, and shape were run on ordinal and 
interval/ratio scaled variables and continuously scaled variables.
An alpha level of 0.05 was used for all statistical analyses. Univariate and 
multivariate repeated measures analyses of variance were run to determine whether there 
was a significant change in physiological measures and clinical scores from admission to
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last assessment. A separate analysis was run for diagnosis of MS, other physiological 
measures, and clinical scales.
Analysis o f  Covariance
A mixed model analysis of covariance (ANCOVA), with LOS and total number 
of admissions as covariates, was conducted to determine whether there was a change in 
mean scores on dependent measures across time period (admission, last assessment) and 
treatment (FGA, SGA). Violation of sphericity was corrected for by means of the 
Greenhouse-Geisser adjustment.
A mixed model ANCOVA was conducted on diagnosis of MS, with LOS and 
total number of admissions as covariates. Results indicated a significant time x treatment 
effect on diagnosis of MS F( 1, 77) = 4.66,/?= .034 (see Figure 1). Patients on SGAs had 
a greater increase in diagnosis of MS from admission {M= .08, SD = .28) to last 
assessment (M= .36, SD = .49) than patients on FGAs (admission, M =  .18, SD = .39; 
last assessment, M =  .22, SD = .42),
For weight, there was a significant main effect of time, F(l,  91) = 9.51, p  = .003. 
Patients weighed less at admission (M -  180.34, SD = 45.22) than at last assessment (M — 
186.43, SD = 39.46). There was significant time x treatment effect on weight F (l, 91) =
7.22, p  = .009. Patients on SGAs had a greater increase in weight from admission (M= 
175.79, SD = 44.29) to last assessment (M= 188.69, SD = 37.91) than patients on FGAs 
(admission, M =  183.80, SD = 46.02; last assessment, M =  184.71, SD — 40.87).
A 2 x 2 mixed model multivariate analysis of covariance (MANCOVA), with 
LOS and total number of admissions as covariates, was performed on six dependent 
variables: BMI, systolic and diastolic blood pressure, HDL, Triglycerides, and fasting
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glucose. Independent variables were time period and treatment. With the use of Wilk’s 
criterion, the combined DVs were not significantly affected by time or treatment. There 
was a nearly significant time x treatment effect on the combined dependent variables F(6, 
45) = 2.12, p  = .069. Univariate tests within the MANCOVA reveal a significant time x 
treatment effect on systolic blood pressure, F( 1, 50) = 7.40,/? = .009. Patients on SGAs 
had a greater increase in systolic blood pressure from admission (A/= 121.07, SD =
11.54) to last assessment (.M=  127.48, SD = 13.00) than patients on FGAs (admission, M  
= 131.85, SD = 16.95; last assessment, M = 122.93, SD = 13.29).
A mixed model ANCOVA on BPRS total scores, with LOS and total number of 
admissions as covariates, indicated a main effect of time, F{ 1, 78) = 37.53,/? = .000. 
Patients had higher BPRS total scores at admission (M=  40.98, SD = 10.81) than at last 
assessment (M= 32.88, SD = 10.14). There was a non-significant main effect of 
treatment and time x treatment effect. A 2 x 2 mixed model multivariate analysis of 
variance (MANCOVA) was performed on the five BPRS subscales: withdrawal, 
cognitive dysfunction, agitation, hostile suspiciousness, and psychotic distortion. The 
combined dependent variables were significantly affected by time, F(5, 74) = 9.81,/? = 
.000. Table 6 shows mean BPRS subscale scores between admission and last assessment. 
No main effect for treatment or time x treatment effect on the combined dependent 
variables was found.
Univariate mixed model ANCOVAs, with LOS and total number of admissions as 
covariates, were conducted on Global Assessment of Functioning (GAF) and MMSE 
scores. There was a significant main effect of time on GAF, F  (1, 87) = 29.63,/? = .000. 
Patients’ GAF was higher at last assessment (M=  47.55, SD = 14.55) than at admission
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(M= 31.62, SD =11.57). Treatment and time x treatment did not significantly affect 
GAF. For MMSE scores, there was significant time x treatment effect, F  (1, 30) = 6.47,/? 
= .016 (see Figure 2). Patients treated with FGAs were more likely to improve on the 
MMSE from admission (M= 21.00, SD = 7.83) to last assessment (M= 27.00, SD =
5.61) than those on SGAs (admission, M — 24.89, SD = 4.78; last assessment, M=  25.79, 
SD = 5.15). Time and treatment did not significantly affect MMSE scores.
Discussion
This study examined the prevalence of MS among schizophrenic and 
schizoaffective patients receiving FGAs and SGAs. Results indicated that over the course 
of one hospital admission, patients treated with SGAs were more likely to meet the 
diagnostic criteria for MS than those on FGAs. Patients receiving SGAs also displayed 
greater increases in weight and systolic blood pressure from first to last assessment than 
those being treated with FGAs. In combination, these results support previous findings 
that metabolic irregularities (Wu et al., 2006), weight gain (Casey, 2005), and 
hypertension (Meltzer, Davidson, Alexander, Glassman, & Vieweg, 2002) are side 
effects associated with SGA use.
Results from this study revealed that the interaction between time and treatment 
significantly affected diagnosis of MS but not the combined physiological risk factors for 
MS. These discrepancies reinforce that the diagnosis of MS is not merely an aggregate of 
the following physiological variables: BMI, blood pressure, HDL, triglycerides, and 
fasting glucose. Instead, MS is the co-occurrence of three of the following conditions: 
obesity, elevated blood pressure, reduced HDL, elevated triglycerides, and elevated 
fasting glucose. In order to meet the criteria for MS, patients did not have to evidence
Patterns and Prevalence 16
abnormalities in all of the aforementioned areas (Expert Panel on Detection, 2001). 
Therefore, the results of the 2x2 mixed model ANCOVA are more appropriate for current 
study than an analysis of the combined physiological DVs. As a result, it can be 
concluded that there is a higher prevalence of MS among patients treated with SGAs than 
those receiving FGAs. This finding supports the main hypothesis of this study.
Results revealed no significant differences in Axis V or BPRS total and scale 
scores from first to last assessment between treatment groups. This finding suggests that 
SGAs and FGAs are similarly effective in reducing psychosis. The current study also 
found that patients treated with FGAs demonstrated greater improvements in MMSE 
scores over the course of one hospital admission than those on SGAs. This finding 
suggests that FGAs benefit cognitive functioning more than SGAs. In combination, these 
results indicate that SGAs are not superior to FGAs in terms of clinical efficacy.
Many researchers and clinicians have asserted the superior therapeutic efficacy of 
SGAs over FGAs (Marder, 2003). However, when studies have collapsed antipsychotics 
across drug type, as was done in the current study, results have indicated that SGAs have 
little or no advantage over FGAs in terms of therapeutic efficacy. Geddes et al. (2000) 
found that after controlling for higher than recommended FGA doses, tolerability and 
clinical efficacy between FGAs and SGAs was similar. In addition, SGAs showed only a 
slight advantage over FGAs in terms of EPS.
Methodological problems with many efficacy studies comparing FGAs to SGAs 
have been identified (see Rosenheck, 2005 for review). Rosenheck (2005) found that the 
quality of life and symptom reduction reported in many SGA efficacy studies may be 
inflated and give unfair advantage to SGAs. After excluding FGA doses below the
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therapeutic range and FGA use without prophylactic anticholinergics, patients on low- 
potency FGAs were not at greater risk of non-adherence, treatment discontinuation, or 
developing EPS than SGAs. These findings indicate that FGAs and SGAs may have 
comparable treatment effectiveness.
Given the lack of support found in the current study for the superiority of SGAs 
on measures of therapeutic efficacy, the slightly lower risk of EPS associated with SGA 
use appears to be abated by the greater risk of weight gain and MS among patients 
receiving SGAs than those on FGAs. Metabolic syndrome is a financial burden. Given 
the constellation of metabolic disorders necessary for establishing a diagnosis, it is not 
surprising that MS is associated with an increased risk of obesity, diabetes, and 
cardiovascular disease (Reaven, 2002). In conjunction with the much greater drug costs 
of SGAs in comparison to FGAs, the annual health care costs of these conditions raise 
concern about the high prevalence of MS among patients receiving SGAs.
In the general population, spending per person was 37% higher in 2001 for obese 
persons than for those who were normal-weight (Thorpe, Florence, Howard, & Joski, 
2004). Health risks associated with obesity include respiratory complications, certain 
cancers, liver and gall bladder disease, and hypertension (Kopelman, 2007). Because 
obesity both exacerbates and causes many health problems (Kopelman, 2007), obesity is 
a societal and economic burden. The United States Department of Health and Human 
Services (2001) estimated that overweight and obesity costs approximately $117 billion 
annually.
Diabetes mellitus and cardiovascular diseases incur some of the highest health 
care costs in the general population annually. The Center for Disease Control and
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Prevention (2003) estimated that the annual direct cost of diabetes is approximately $92 
billion in the United States. Diabetes also carries a high risk of mortality. In 2003, 
diabetes was the sixth leading cause of death (Hoyert, Kung, & Smith, 2005). The loss of 
productivity associated with diabetes’ high mortality and morbidity rates contribute to the 
$40 billion in indirect costs of this metabolic disorder annually.
Cardiovascular disease is the leading cause of death and disability worldwide 
(Thom et al., 2006). Common types of cardiovascular disease include hypertension, 
coronary artery disease, heart failure, and stroke. Approximately 34% of all deaths in the 
United States in 2004 were related to cardiovascular disease. Included in the estimates of 
indirect costs of cardiovascular diseases is the loss of productivity associated with the 
high rate of morbidity and mortality of these diseases. In the general population, 
cardiovascular disease is the most costly disease in the United States incurring 
approximately $400 billion annually (Thom et al., 2006).
In addition to causing economic strain, the personal costs associated with MS are 
great. Metabolic syndrome adversely impacts one’s quality of life (Gardner,
Montgomery, & Parker, 2006). In addition, weight gain, which increases the risk of MS 
(Everson et al., 1998), can lead to treatment non-compliance (Awad & Vorunganti,
2004). De Hert et al. (2006) found that patients with schizophrenia who experienced 
recent weight gain had lower self-esteem and psychosocial adjustment than patients who 
had not gained weight. Recent weight gain also leads to discontinuation of treatment.
When establishing the cost-effectiveness of antipsychotics, both the financial and 
personal costs need to be evaluated. Second generation antipsychotics gained popularity 
because they carry a lower risk of EPS than FGAs. Due to the debilitating nature of EPS,
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it was believed that SGAs contributed to a higher quality of life than FGAs. However, 
given the large economic and personal costs of MS and the higher prevalence of MS 
found in this study among patients receiving SGAs than those on FGAs, the cost- 
effectiveness of SGAs needs to be reexamined. The higher risk of MS and lack of support 
for the superiority of SGAs in terms of clinical efficacy found in this study suggest that 
the benefits of SGAs may not outweigh the side effects and financial cost of this class of 
antipsychotics. Further research is needed to establish the direct and indirect costs of 
SGAs as well as morbidity and mortality estimates of the side effects of SGAs (e.g., 
obesity, elevated blood pressure, and MS). In conjunction with the findings from this 
study, these analyses could call into question the use of SGAs as a first-line treatment for 
schizophrenia.
A key limitation of this research concerns the generalizability of the results. As 
with all quasi-experimental designs, the findings of this study should be regarded with 
caution. The small within group sample sizes of this study further limits the analyses of 
clinical efficacy between specific FGAs and SGAs. Therefore, future research should 
replicate this study using larger within group samples to determine the therapeutic 
efficacy and effectiveness of specific SGAs. Furthermore, future efforts should also be 
directed at determining how dose might affect the different side effect profiles of SGAs.
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Table 1
Demographic Variables
/ %
Gender
Male 49 49.5
Female 50 50.5
Ethnicity
African American 68 68.7
Caucasian 30 30.3
Hispanic 1 1.0
Education History
Less than High School 7 7.5
Some High School 24 25.8
Diploma or GED 26 28.0
Some College 19 20.4
College Degree 13 14.0
Graduate Degree 4 4.3
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Table 2
Primary Psychiatric Diagnoses and Psychosocial and Environmental Problems
Diagnostic Categories
/  %
Axis I and Axis II Diagnoses
Schizophrenia 39 39.4
Schizoaffective Disorders 60 60.6
Substance Disorders 28 28.3
Personality Disorders 18 18.2
Mild Mental Retardation 7 7.1
Axis IV Psychosocial and Environmental Problems
Primary Support Group 24 24.2
Social Environment 5 5.1
Educational 0 0.0
Occupational 9 9.1
Housing 23 23.2
Economic 2 2.0
Access to Health Care 37 37.4
Legal System/Crime 30 30.3
Other 1 1.0
Note. Percentage reflects percent of subjects with a diagnosis or problem in a given 
category. Many subjects had more than one diagnosis and problem.
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Table 3
Antipsychotic Doses
Medication / %
Daily Dose (mgs) 
Min Max M Mdn SD
FGAs (n = 56)
fluphenazine HC1 8 8.1 5.0 20.0 13.1 15.0 4.6
fluphenazine decanoate 13 13.1 0.2 5.4 2.7 3.6 1.7
haloperidol 19 19.2 5.0 45.0 19.3 20.0 10.2
haloperidol decanoate* 20 20.2 1.8 14.3 7.5 7.1 4.6
thioridazine 2 2.0 600.0 800.0 700.0 700.0 141.4
thiothixene 5 5.1 15.0 40.0 30.0 30.0 10.6
SGAs (n = 43)
aripiprazole 2 2.0 30.0 30.0 30.0 30.0 0.0
clozapine 5 5.1 200.0 500.0 355.0 400.0 135.1
risperidone oral 12 12.1 4.0 8.0 5.7 6.0 1.4
risperidone consta 3 3.0 3.6 3.6 3.6 3.6 0.0
olanzapine 17 17.2 10.0 30.0 19.4 20.0 4.3
quetiapine 3 3.0 200.0 900.0 600.0 700.0 360.6
ziprasidone 4 4.0 160.0 160.0 160.0 160.0 0.0
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Table 4
Metabolic Syndrome Among FGA Patients at Last Assessment
Metabolic Syndrome
Normal Range High Risk
NCEP criteria / % / %
Fasting Glucose >110 mg/dl 49 87.5 7 12.5
Hypertension > 130/80 33 58.9 23 41.1
Triglycerides >150 mg/dl 39 69.6 16 28.6
HDL Cholesterol <40 mg/dl in women 26 46.4 12 21.4
<50 mg/dl in men
BMI > 29.4 kg/m2 36 64.3 20 35.7
MS any 3 of the above traits 38 67.9 12 21.4
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Table 5
Metabolic Syndrome Among SGA Patients at Last Assessment
Metabolic Syndrome
Normal Range High Risk
NCEP criteria / % / %
Fasting Glucose >110 mg/dl 34 79.1 8 18.6
Hypertension > 130/80 22 51.2 21 48.8
Triglycerides > 150 mg/dl 27 62.8 13 30.2
HDL Cholesterol <40 mg/dl in women 20 46.5 18 41.9
<50 mg/dl in men
BMI > 29.4 kg/m2 19 44.2 24 55.8
MS any 3 of the above traits 25 58.1 14 32.6
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Table 6
Mean BPRS Subscales at Admission and Last Assessment
Admission Last Assessment
BPRS Subscale Mean SD Mean SD
Withdrawal 8.41 4.32 6.68 2.74
Cognitive Dysfunction 5.30 2.74 3.90 2.05
Agitation 6.26 3.25 4.79 2.15
Hostile Suspiciousness 5.45 3.Q6 3.99 2.08
Psychotic Distortion 6.26 2.61 4.18 2.08
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Figure 1 
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Figure 2
Estimated marginal means for MMSE scores
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